228 related articles for article (PubMed ID: 28541791)
1. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
2. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
3. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.
Olszewski AJ; Dusetzina SB; Trivedi AN; Davidoff AJ
J Clin Oncol; 2018 Oct; 36(28):2879-2886. PubMed ID: 30113885
[TBL] [Abstract][Full Text] [Related]
4. Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and Use.
Fung V; Price M; Cheng D; Patel TA; Yang Z; Hsu J; Alegria M; Newhouse JP
JAMA Health Forum; 2024 Feb; 5(2):e235152. PubMed ID: 38306091
[TBL] [Abstract][Full Text] [Related]
5. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
[TBL] [Abstract][Full Text] [Related]
6. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
Glynn A; Hernandez I; Roberts ET
Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
8. The Association Between Medicare Low-Income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer.
Chou YT; Farley JF; Stinchcombe TE; Proctor AE; Lafata JE; Dusetzina SB
J Natl Cancer Inst; 2020 Jun; 112(6):637-646. PubMed ID: 31501872
[TBL] [Abstract][Full Text] [Related]
9. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
10. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.
Olszewski AJ; Barth PM; Reagan JL
Cancer Med; 2019 Nov; 8(16):6945-6954. PubMed ID: 31566898
[TBL] [Abstract][Full Text] [Related]
11. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Ailawadhi S; Frank RD; Advani P; Swaika A; Temkit M; Menghani R; Sharma M; Meghji Z; Paulus S; Khera N; Hashmi SK; Paulus A; Kakar TS; Hodge DO; Colibaseanu DT; Vizzini MR; Roy V; Colon-Otero G; Chanan-Khan AA
Cancer Med; 2017 Dec; 6(12):2876-2885. PubMed ID: 29105343
[TBL] [Abstract][Full Text] [Related]
12. The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.
Hartung DM; Johnston KA; McGregor JC; Bourdette DN
Mult Scler Relat Disord; 2020 Nov; 46():102554. PubMed ID: 33032059
[TBL] [Abstract][Full Text] [Related]
13. Cognition and take-up of subsidized drug benefits by Medicare beneficiaries.
Kuye IO; Frank RG; McWilliams JM
JAMA Intern Med; 2013 Jun; 173(12):1100-7. PubMed ID: 23649604
[TBL] [Abstract][Full Text] [Related]
14. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
[TBL] [Abstract][Full Text] [Related]
15. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
16. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Madan S; Lacy MQ; Dispenzieri A; Gertz MA; Buadi F; Hayman SR; Detweiler-Short K; Dingli D; Zeldenrust S; Lust J; Greipp PR; Rajkumar SV; Kumar S
Blood; 2011 Aug; 118(7):1763-5. PubMed ID: 21673347
[TBL] [Abstract][Full Text] [Related]
18. Responses to Medicare drug costs among near-poor versus subsidized beneficiaries.
Fung V; Reed M; Price M; Brand R; Dow WH; Newhouse JP; Hsu J
Health Serv Res; 2013 Oct; 48(5):1653-68. PubMed ID: 23663197
[TBL] [Abstract][Full Text] [Related]
19. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
20. Patterns of prescription drug expenditures and medication adherence among medicare part D beneficiaries with and without the low-income supplement.
Yala SM; Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF
BMC Health Serv Res; 2014 Dec; 14():665. PubMed ID: 25526892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
